Association between cannabis use and symptom dimensions in schizophrenia spectrum disorders: an individual participant data meta-analysis on 3053 individuals.

Journal: EClinicalMedicine

Volume: 64

Issue: 

Year of Publication: 

Affiliated Institutions:  PSYR, CNRL, INSERM U, CNRS UMR, UCBL, Bron, France. Laboratoire de Psychopathologie et Processus de Santé, Université Paris Cité, F-, France. Swiss Research Institute for Public Health and Addiction ISGF, University of Zurich, Zurich, Switzerland. Department of Psychiatry, McGill University, Montreal, Canada. Medical School Hamburg, University of Applied Sciences and Medical University, Hamburg, Germany. NORMENT Centre, Division of Mental Health and Addiction, Oslo University Hospital and University of Oslo, Oslo, Norway. Department of Psychiatry, Hotchkiss Brain Institute, University of Calgary, Calgary, Canada. Department of Neurosciences and Mental Health, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. Department of Psychiatry, Psychotherapy und Psychosomatic, Vivantes Klinikum am Urban und Vivantes Klinikum im Friedrichshain, Berlin, Germany. Centre for Mental Health, County Hospitals Darmstadt-Dieburg, Groß-Umstadt, Germany. Department of Psychiatry and Psychotherapy, Ludwig Maximillian University Munich, Munich, Germany. Clienia Littenheid AG, Psychiatrische Tagesklinik Frauenfeld, , Frauenfeld, Switzerland. Department of Experimental Psychology, University of Bristol, Bristol, UK. Etiopathogenesis and Treatment of Severe Mental Disorders (MERITT), Institut de Recerca Sant Joan de Déu, Spain. Université Paris Cité, INSERM UMR, Institute of Psychiatry and Neuroscience of Paris France, France. Department of Neuroscience, San Luigi Gonzaga University Hospital, , Orbassano, Italy. Department of Neuroscience, Imaging, Clinical Sciences, University of Chieti-Pescara, Italy. National Institute of Mental Health, Klecany, Czech Republic. Department of Psychiatry, QEII Health Sciences Centre, Dalhousie University, Halifax, Nova Scotia, Canada. Neuroscience Institute, University of Cape Town, Cape Town, South Africa. Department of Psychiatry, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa. Barcelona Clinic Schizophrenia Unit, Neuroscience Institute, Hospital Clínic of Barcelona, IDIBAPS, CIBERSAM, University of Barcelona, Barcelona, Spain. Psychiatric Genetics Unit, Vall d'Hebron Research Institute (VHIR), Biomedical Research Networking Center for Mental Health Network (CIBERSAM), Barcelona, Spain. Universitäre Psychiatrische Kliniken (UPK) Basel, Universität Basel, Wilhelm Klein-Str. , Basel, Switzerland. Boston Medical Center, Department of Psychiatry, Massachusetts Avenue, th Floor, Boston, MA, , United States of America. Lille University, Inserm U-LilNcog-Lille Neuroscience & Cognition, Plasticity and Subjectivity Team, F-, Lille, France. Service de biostatistique, Hospices Civils de Lyon, Lyon, France.

Abstract summary 

The association between cannabis use and positive symptoms in schizophrenia spectrum disorders is well documented, especially via meta-analyses. Yet, findings are inconsistent regarding negative symptoms, while other dimensions such as disorganization, depression, and excitement, have not been investigated. In addition, meta-analyses use aggregated data discarding important confounding variables which is a source of bias.PubMed, ScienceDirect and PsycINFO were used to search for publications from inception to September 27, 2022. We contacted the authors of relevant studies to extract raw datasets and perform an Individual Participant Data meta-analysis (IPDMA). Inclusion criteria were: psychopathology of individuals with schizophrenia spectrum disorders assessed by the Positive and Negative Syndrome Scale (PANSS); cannabis-users had to either have a diagnosis of cannabis use disorder or use cannabis at least twice a week. The main outcomes were the PANSS subscores extracted via the 3-factor (positive, negative and general) and 5-factor (positive, negative, disorganization, depression, excitement) structures. Preregistration is accessible via Prospero: ID CRD42022329172.Among the 1149 identified studies, 65 were eligible and 21 datasets were shared, totaling 3677 IPD and 3053 complete cases. The adjusted multivariate analysis revealed that relative to non-use, cannabis use was associated with higher severity of positive dimension (3-factor: Adjusted Mean Difference, aMD = 0.34, 95% Confidence Interval, CI = [0.03; 0.66]; 5-factor: aMD = 0.38, 95% CI = [0.08; 0.63]), lower severity of negative dimension (3-factor: aMD = -0.49, 95% CI [-0.90; -0.09]; 5-factor: aMD = -0.50, 95% CI = [-0.91; -0.08]), higher severity of excitement dimension (aMD = 0.16, 95% CI = [0.03; 0.28]). No association was found between cannabis use and disorganization (aMD = -0.13, 95% CI = [-0.42; 0.17]) or depression (aMD = -0.14, 95% CI = [-0.34; 0.06]).No causal relationship can be inferred from the current results. The findings could be in favor of both a detrimental and beneficial effect of cannabis on positive and negative symptoms, respectively. Longitudinal designs are needed to understand the role of cannabis is this association. The reported effect sizes are small and CIs are wide, the interpretation of findings should be taken with caution.This research did not receive any specific grant or funding. Primary financial support for authors was provided by Le Vinatier Psychiatric Hospital.

Authors & Co-authors:  Argote Sescousse Brunelin Baudin Schaub Rabin Schnell Ringen Andreassen Addington Brambilla Delvecchio Bechdolf Wobrock Schneider-Axmann Herzig Mohr Vila-Badia Rodie Mallet Ricci Martinotti Knížková Rodriguez Cookey Tibbo Scheffler Asmal Garcia-Rizo Amoretti Huber Thibeau Kline Fakra Jardri Nourredine Rolland

Study Outcome 

Source Link: Visit source

Statistics
Citations :  Koskinen J., Lohonen J., Koponen H., Isohanni M., Miettunen J. Rate of cannabis use disorders in clinical samples of patients with schizophrenia: a meta-analysis. Schizophr Bull. 2010;36(6):1115–1130. doi: 10.1093/schbul/sbp031.
Authors :  37
Identifiers
Doi : 102199
SSN : 2589-5370
Study Population
Male,Female
Mesh Terms
Other Terms
Cannabis;Individual participant data;Meta-analysis;PANSS;Schizophrenia;Symptom dimensions
Study Design
Study Approach
Country of Study
Publication Country
England